Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FMCLF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
JSKN-003
|
|||||
| Synonyms |
JSKN003; JSKN 003
Click to Show/Hide
|
|||||
| Organization |
Alphamab Oncology; Alphamab Australia Co. Pty Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 2 Indication(s)
Advanced malignant solid neoplasm [ICD11:2E92]
Phase 1
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.